Levosimendan Eql Pharma (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium concentrations. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces both preload and afterload, thereby improving overall cardiac performance.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. The prescriber selects the appropriate loading dose, infusion rate, and duration, following local guidelines and product labeling.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians must weigh the clinical need against the uncertain safety profile and discuss options with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Compared with traditional inotropes such as dobutamine, levosimendan enhances contractility without increasing intracellular calcium, which may reduce the risk of calcium‑mediated arrhythmias. Additionally, its vasodilatory action lowers afterload, offering a dual benefit that some clinicians prefer for patients with both low output and high systemic resistance.

Levosimendan injectable solution must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Levosimendan is given as an intravenous infusion. Depending on the clinical protocol, a loading dose may be administered over a short period followed by a continuous maintenance infusion. Administration is performed under continuous cardiovascular monitoring in a setting equipped for rapid intervention if needed.

The most critical adverse events include severe hypotension, life‑threatening arrhythmias, and myocardial ischaemia. Patients should be closely monitored for sudden drops in blood pressure, abnormal heart rhythms, and signs of chest pain or reduced coronary perfusion throughout the infusion and for a period afterward.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should be avoided in individuals with severe hypotension, obstructive cardiac lesions, or uncontrolled ventricular arrhythmias. Caution is also advised in patients with significant renal or hepatic impairment, where dose adjustments may be required.